Neurogene Inc. (NGNE)
NasdaqGM · USD · Healthcare · Biotechnology
$23.54 (-0.04%) as of
Key statistics
- Market cap
- 471.07M
- Forward P/E
- -4.11
- EPS (TTM)
- -5.04
- Dividend yield
- 0.00%
- 52-week range
- 15.93 – 43.66
- Beta
- 2.09
- Profit margin
- 0.00%
- Analyst target
- $77.88
- Volume
- 123.20k
About Neurogene Inc.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New York, NY, United States
- Employees
- 131
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.